{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:47:58Z","timestamp":1782190078009,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/aps.2013.196","type":"journal-article","created":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T07:56:40Z","timestamp":1399017400000},"page":"613-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models"],"prefix":"10.1038","volume":"35","author":[{"given":"Pang-ke","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-shan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,2]]},"reference":[{"key":"BFaps2013196_CR1","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","volume":"362","author":"W Yang","year":"2010","unstructured":"Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090\u2013101.","journal-title":"N Engl J Med"},{"key":"BFaps2013196_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.4103\/2230-8210.117219","volume":"17","author":"S Kalra","year":"2013","unstructured":"Kalra S, Mukherjee JJ, Venkataraman S, Bantwal G, Shaikh S, Saboo B, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab 2013; 17: 819\u201334.","journal-title":"Indian J Endocrinol Metab"},{"key":"BFaps2013196_CR3","doi-asserted-by":"publisher","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"EM Wright","year":"2001","unstructured":"Wright EM . Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFaps2013196_CR4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","volume":"74","author":"MA Hediger","year":"1994","unstructured":"Hediger MA, Rhoads DB . Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994; 74: 993\u20131026.","journal-title":"Physiol Rev"},{"key":"BFaps2013196_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/350354a0","volume":"350","author":"E Turk","year":"1991","unstructured":"Turk E, Zabel B, Mundlos S, Wright EM . Glucose\/galactose malabsorption caused by a defect in the Na+\/glucose cotransporter. Nature 1991; 350: 354\u20136.","journal-title":"Nature"},{"key":"BFaps2013196_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00439-002-0820-5","volume":"111","author":"LP Van den Heuvel","year":"2002","unstructured":"Van den Heuvel LP, Assink K, Willemsen M, Monnens L . Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111: 544\u20137.","journal-title":"Hum Genet"},{"key":"BFaps2013196_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"JR Ehrenkranz","year":"2005","unstructured":"Ehrenkranz JR, Lewis NG, Kahn CR, Roth J . Phlorizin: a review. Diabetes Metab Res Rev 2005; 21: 31\u20138.","journal-title":"Diabetes Metab Res Rev"},{"key":"BFaps2013196_CR8","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","volume":"48","author":"A Oku","year":"1999","unstructured":"Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794\u2013800.","journal-title":"Diabetes"},{"key":"BFaps2013196_CR9","first-page":"785","volume":"12","author":"J Calado","year":"2009","unstructured":"Calado J . Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12: 785\u201398.","journal-title":"IDrugs"},{"key":"BFaps2013196_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1517\/17425255.2013.791282","volume":"9","author":"EM Lamos","year":"2013","unstructured":"Lamos EM, Younk LM, Davis SN . Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013; 9: 763\u201375.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFaps2013196_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83\u201390.","journal-title":"Diabetes Obes Metab"},{"key":"BFaps2013196_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1124\/dmd.112.049551","volume":"41","author":"Z Miao","year":"2013","unstructured":"Miao Z, Nucci G, Amin N, Sharma R, Mascitti V, Tugnait M, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos 2013; 41: 445\u201356.","journal-title":"Drug Metab Dispos"},{"key":"BFaps2013196_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723\u20139.","journal-title":"Diabetes"},{"key":"BFaps2013196_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","volume":"132","author":"K Arakawa","year":"2001","unstructured":"Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, et al. Improved diabetic syndrome in C57BL\/KsJ-db\/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132: 578\u201386.","journal-title":"Br J Pharmacol"},{"key":"BFaps2013196_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1463-1326.2011.01518.x","volume":"14","author":"L Thomas","year":"2012","unstructured":"Thomas L, Grempler R, Eckhardt M, Himmelsbach F, Sauer A, Klein T, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab 2012; 14: 94\u20136.","journal-title":"Diabetes Obes Metab"},{"key":"BFaps2013196_CR16","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.2337\/diabetes.53.2007.S119","volume":"53","author":"RP Robertson","year":"2004","unstructured":"Robertson RP, Harmon J, Tran PO, Poitout V . Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53: S119\u201324.","journal-title":"Diabetes"},{"key":"BFaps2013196_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011; 60: 890\u20138.","journal-title":"Diabetes"},{"key":"BFaps2013196_CR18","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.2337\/diabetes.54.9.2755","volume":"54","author":"C Kjorholt","year":"2005","unstructured":"Kjorholt C, Akerfeldt MC, Biden TJ, Laybutt DR . Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta cell differentiation and secretory function in the db\/db mouse model of diabetes. Diabetes 2005; 54: 2755\u201363.","journal-title":"Diabetes"},{"key":"BFaps2013196_CR19","doi-asserted-by":"publisher","first-page":"14112","DOI":"10.1074\/jbc.274.20.14112","volume":"274","author":"JC Jonas","year":"1999","unstructured":"Jonas JC, Sharma A, Hasenkamp W, Ilkova H, Patan\u00e8 G, Laybutt R, et al. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem 1999; 274: 14112\u201321.","journal-title":"J Biol Chem"},{"key":"BFaps2013196_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI113157","volume":"80","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Shulman GI, Zawalich W, DeFronzo RA . Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987; 80: 1037\u201344.","journal-title":"J Clin Invest"},{"key":"BFaps2013196_CR21","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555.","journal-title":"PLoS One"},{"key":"BFaps2013196_CR22","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1463-1326.2010.01291.x","volume":"12","author":"FR Macdonald","year":"2010","unstructured":"Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010; 12: 1004\u201312.","journal-title":"Diabetes Obes Metab"},{"key":"BFaps2013196_CR23","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1016\/S0021-9258(18)47618-1","volume":"262","author":"H Wallberg-Henriksson","year":"1987","unstructured":"Wallberg-Henriksson H, Zetan N, Henriksson J . Reversibility of decreased insulin-stimulated glucose transport capacity in diabetic muscle with in vitro incubation. Insulin is not required. J Biol Chem 1987; 262: 7665\u201371.","journal-title":"J Biol Chem"},{"key":"BFaps2013196_CR24","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1021\/jm8013019","volume":"52","author":"WN Washburn","year":"2009","unstructured":"Washburn WN . Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 2009; 52: 1785\u201394.","journal-title":"J Med Chem"},{"key":"BFaps2013196_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3810\/pgm.2013.05.2672","volume":"125","author":"JS Freeman","year":"2013","unstructured":"Freeman JS . Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med 2013; 125: 214\u201326.","journal-title":"Postgrad Med"},{"key":"BFaps2013196_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/15733998113099990069","volume":"9","author":"MS Akash","year":"2013","unstructured":"Akash MS, Rehman K, Chen S . Goto-Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Curr Diabetes Rev 2013; 9: 387\u201396.","journal-title":"Curr Diabetes Rev"},{"key":"BFaps2013196_CR27","unstructured":"Herberg L, Leiter EH . Obesity\/diabetes in mice with mutations in the leptin or leptin receptor genes. In: Shima, AAF, Shafrir, E (Eds), Animal Models of Diabetes A Primer. Harwood academic publishers, Amsterdam, 2001. pp 63\u2013107."},{"key":"BFaps2013196_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1124\/jpet.108.140210","volume":"327","author":"Y Fujimori","year":"2008","unstructured":"Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M . Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268\u201376.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2013196_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejphar.2009.03.007","volume":"609","author":"Y Fujimori","year":"2009","unstructured":"Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609: 148\u201354.","journal-title":"Eur J Pharmacol"},{"key":"BFaps2013196_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fendo.2013.00146","volume":"4","author":"TG Ara\u00fajo","year":"2013","unstructured":"Ara\u00fajo TG, Oliveira AG, Saad MJ . Insulin-resistance-associated compensatory mechanisms of pancreatic beta cells: a current opinion. Front Endocrinol (Lausanne) 2013; 4: 146.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"BFaps2013196_CR31","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.2337\/dc09-S302","volume":"32","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA, Tripathy D . Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009; 32: S157\u201363.","journal-title":"Diabetes Care."},{"key":"BFaps2013196_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2337\/diab.37.6.667","volume":"37","author":"RA DeFronzo","year":"1988","unstructured":"DeFronzo RA . The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667\u201387.","journal-title":"Diabetes"},{"key":"BFaps2013196_CR33","doi-asserted-by":"publisher","first-page":"14959","DOI":"10.1074\/jbc.271.25.14959","volume":"271","author":"TS Tsao","year":"1996","unstructured":"Tsao TS, Burcelin R, Charron MJ . Regulation of hexokinase II gene expression by glucose flux in skeletal muscle. J Biol Chem 1996; 271: 14959\u201363.","journal-title":"J Biol Chem"},{"key":"BFaps2013196_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1172\/JCI115865","volume":"90","author":"RP Robertson","year":"1992","unstructured":"Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF . Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J Clin Invest 1992; 90: 320\u20135.","journal-title":"J Clin Invest"},{"key":"BFaps2013196_CR35","first-page":"255","volume":"18","author":"L Rossetti","year":"1995","unstructured":"Rossetti L . Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med 1995; 18: 255\u201360.","journal-title":"Clin Invest Med"},{"key":"BFaps2013196_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0749-0690(18)30058-2","volume":"15","author":"AD Mooradian","year":"1999","unstructured":"Mooradian AD, Thurman JE . Glucotoxicity: potential mechanisms. Clin Geriatr Med 1999; 15: 255.","journal-title":"Clin Geriatr Med"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2013196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2013196","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2013196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:29:51Z","timestamp":1684412991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2013196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFaps2013196"],"URL":"https:\/\/doi.org\/10.1038\/aps.2013.196","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"20 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}